Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

Sally Arai; Mukta Arora; Tao Wang; Stephen R. Spellman; Wensheng He; Daniel R. Couriel; Alvaro Urbano-Ispizua; Corey S. Cutler; Andrea A. Bacigalupo; Minoo Battiwalla; Mary E. Flowers; Mark B. Juckett; Stephanie J. Lee; Alison W. Loren; Thomas R. Klumpp; Susan E. Prockup; Olle T H Ringdén; Bipin N. Savani; Gérard Socié; Kirk R. Schultz; Thomas Spitzer; Takanori Teshima; Christopher N. Bredeson; David A. Jacobsohn; Robert J. Hayashi; William R. Drobyski; Haydar A. Frangoul; Görgün Akpek; Vincent T. Ho; Victor A. Lewis; Robert Peter Gale; John Koreth; Nelson J. Chao; Mahmoud D. Aljurf; Brenda W. Cooper; Mary J. Laughlin; Jack W. Hsu; Peiman Hematti; Leo F. Verdonck; Melhelm M. Solh; Maxim Norkin; Vijay Reddy; Rodrigo Martino; Shahinaz Gadalla; Jenna D. Goldberg; Philip L. McCarthy; José A. Pérez-Simón; Nandita Khera; Ian D. Lewis; Yoshiko Atsuta; Richard F. Olsson; Wael Saber; Edmund K. Waller; Didier Blaise; Joseph A. Pidala; Paul J. Martin; Prakash Satwani; Martin Bornhäuser; Yoshihiro Inamoto; Daniel J. Weisdorf; Mary M. Horowitz; Steven Z. Pavletic

doi:10.1016/j.bbmt.2014.10.021

Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

Sally Arai, Mukta Arora, Tao Wang, Stephen R. Spellman, Wensheng He, Daniel R. Couriel, Alvaro Urbano-Ispizua, Corey S. Cutler, Andrea A. Bacigalupo, Minoo Battiwalla, Mary E. Flowers, Mark B. Juckett, Stephanie J. Lee, Alison W. Loren, Thomas R. Klumpp, Susan E. Prockup, Olle T H Ringdén, Bipin N. Savani, Gérard Socié, Kirk R. SchultzThomas Spitzer, Takanori Teshima, Christopher N. Bredeson, David A. Jacobsohn, Robert J. Hayashi, William R. Drobyski, Haydar A. Frangoul, Görgün Akpek, Vincent T. Ho, Victor A. Lewis, Robert Peter Gale, John Koreth, Nelson J. Chao, Mahmoud D. Aljurf, Brenda W. Cooper, Mary J. Laughlin, Jack W. Hsu, Peiman Hematti, Leo F. Verdonck, Melhelm M. Solh, Maxim Norkin, Vijay Reddy, Rodrigo Martino, Shahinaz Gadalla, Jenna D. Goldberg, Philip L. McCarthy, José A. Pérez-Simón, Nandita Khera, Ian D. Lewis, Yoshiko Atsuta, Richard F. Olsson, Wael Saber, Edmund K. Waller, Didier Blaise, Joseph A. Pidala, Paul J. Martin, Prakash Satwani, Martin Bornhäuser, Yoshihiro Inamoto, Daniel J. Weisdorf, Mary M. Horowitz, Steven Z. Pavletic

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

247 Scopus citations

Abstract

Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio=1.19, P<.0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.

Original language	English (US)
Pages (from-to)	266-274
Number of pages	9
Journal	Biology of Blood and Marrow Transplantation
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.bbmt.2014.10.021
State	Published - Feb 1 2015

Bibliographical note

Funding Information:
Financial disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI) (U24-CA76518), and the National Institute of Allergy and Infectious Diseases (NIAID) (U24-CA76518); Grant/Cooperative Agreement 5U01HL069294 from the NHLBI and NCI ; contract HHSH234200637015C with Health Resources and Services Administration; 2 grants ( N00014-06-1-0704 and N00014-08-1-0058 ) from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad ; Be The Match Foundation ; Blue Cross and Blue Shield Association ; Buchanan Family Foundation ; CaridianBCT ; Celgene Corporation ; CellGenix , GmbH ; Fresenius-Biotech North America, Inc. ; Gamida Cell Teva Joint Venture Ltd. ; Genentech, Inc. ; Genzyme Corporation ; GlaxoSmithKline ; HistoGenetics, Inc. ; Kiadis Pharma ; The Medical College of Wisconsin; Merck & Co, Inc. ; Millennium: The Takeda Oncology Co. ; Milliman USA, Inc. ; Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Optum Healthcare Solutions, Inc. ; Osiris Therapeutics, Inc. ; Otsuka America Pharmaceutical, Inc. ; RemedyMD ; Sanofi ; Seattle Genetics ; Sigma-Tau Pharmaceuticals ; Soligenix, Inc. ; StemCyte, A Global Cord Blood Therapeutics Co. ; Stemsoft Software, Inc. ; Swedish Orphan Biovitrum ; Tarix Pharmaceuticals ; Teva Neuroscience, Inc. ; Therakos ; and WellPoint The views expressed in this article do not reflect the official policy or position of the NIH, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.

Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.

Keywords

Allogeneic transplant
CGVHD
Incidence
Nonrelapse mortality

Publisher link

10.1016/j.bbmt.2014.10.021

Find It

Find It at U of M Libraries

Cite this

Arai, S., Arora, M., Wang, T., Spellman, S. R., He, W., Couriel, D. R., Urbano-Ispizua, A., Cutler, C. S., Bacigalupo, A. A., Battiwalla, M., Flowers, M. E., Juckett, M. B., Lee, S. J., Loren, A. W., Klumpp, T. R., Prockup, S. E., Ringdén, O. T. H., Savani, B. N., Socié, G., ... Pavletic, S. Z. (2015). Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 21(2), 266-274. https://doi.org/10.1016/j.bbmt.2014.10.021

Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. / Arai, Sally; Arora, Mukta; Wang, Tao et al.
In: Biology of Blood and Marrow Transplantation, Vol. 21, No. 2, 01.02.2015, p. 266-274.

Research output: Contribution to journal › Article › peer-review

Arai, S, Arora, M, Wang, T, Spellman, SR, He, W, Couriel, DR, Urbano-Ispizua, A, Cutler, CS, Bacigalupo, AA, Battiwalla, M, Flowers, ME, Juckett, MB, Lee, SJ, Loren, AW, Klumpp, TR, Prockup, SE, Ringdén, OTH, Savani, BN, Socié, G, Schultz, KR, Spitzer, T, Teshima, T, Bredeson, CN, Jacobsohn, DA, Hayashi, RJ, Drobyski, WR, Frangoul, HA, Akpek, G, Ho, VT, Lewis, VA, Gale, RP, Koreth, J, Chao, NJ, Aljurf, MD, Cooper, BW, Laughlin, MJ, Hsu, JW, Hematti, P, Verdonck, LF, Solh, MM, Norkin, M, Reddy, V, Martino, R, Gadalla, S, Goldberg, JD, McCarthy, PL, Pérez-Simón, JA, Khera, N, Lewis, ID, Atsuta, Y, Olsson, RF, Saber, W, Waller, EK, Blaise, D, Pidala, JA, Martin, PJ, Satwani, P, Bornhäuser, M, Inamoto, Y, Weisdorf, DJ, Horowitz, MM & Pavletic, SZ 2015, 'Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research', Biology of Blood and Marrow Transplantation, vol. 21, no. 2, pp. 266-274. https://doi.org/10.1016/j.bbmt.2014.10.021

@article{69ff416ce4164024b32c8e5fcb4ab244,

title = "Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research",

abstract = "Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio=1.19, P<.0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.",

keywords = "Allogeneic transplant, CGVHD, Incidence, Nonrelapse mortality",

author = "Sally Arai and Mukta Arora and Tao Wang and Spellman, {Stephen R.} and Wensheng He and Couriel, {Daniel R.} and Alvaro Urbano-Ispizua and Cutler, {Corey S.} and Bacigalupo, {Andrea A.} and Minoo Battiwalla and Flowers, {Mary E.} and Juckett, {Mark B.} and Lee, {Stephanie J.} and Loren, {Alison W.} and Klumpp, {Thomas R.} and Prockup, {Susan E.} and Ringd{\'e}n, {Olle T H} and Savani, {Bipin N.} and G{\'e}rard Soci{\'e} and Schultz, {Kirk R.} and Thomas Spitzer and Takanori Teshima and Bredeson, {Christopher N.} and Jacobsohn, {David A.} and Hayashi, {Robert J.} and Drobyski, {William R.} and Frangoul, {Haydar A.} and G{\"o}rg{\"u}n Akpek and Ho, {Vincent T.} and Lewis, {Victor A.} and Gale, {Robert Peter} and John Koreth and Chao, {Nelson J.} and Aljurf, {Mahmoud D.} and Cooper, {Brenda W.} and Laughlin, {Mary J.} and Hsu, {Jack W.} and Peiman Hematti and Verdonck, {Leo F.} and Solh, {Melhelm M.} and Maxim Norkin and Vijay Reddy and Rodrigo Martino and Shahinaz Gadalla and Goldberg, {Jenna D.} and McCarthy, {Philip L.} and P{\'e}rez-Sim{\'o}n, {Jos{\'e} A.} and Nandita Khera and Lewis, {Ian D.} and Yoshiko Atsuta and Olsson, {Richard F.} and Wael Saber and Waller, {Edmund K.} and Didier Blaise and Pidala, {Joseph A.} and Martin, {Paul J.} and Prakash Satwani and Martin Bornh{\"a}user and Yoshihiro Inamoto and Weisdorf, {Daniel J.} and Horowitz, {Mary M.} and Pavletic, {Steven Z.}",

note = "Funding Information: Financial disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI) (U24-CA76518), and the National Institute of Allergy and Infectious Diseases (NIAID) (U24-CA76518); Grant/Cooperative Agreement 5U01HL069294 from the NHLBI and NCI ; contract HHSH234200637015C with Health Resources and Services Administration; 2 grants ( N00014-06-1-0704 and N00014-08-1-0058 ) from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad ; Be The Match Foundation ; Blue Cross and Blue Shield Association ; Buchanan Family Foundation ; CaridianBCT ; Celgene Corporation ; CellGenix , GmbH ; Fresenius-Biotech North America, Inc. ; Gamida Cell Teva Joint Venture Ltd. ; Genentech, Inc. ; Genzyme Corporation ; GlaxoSmithKline ; HistoGenetics, Inc. ; Kiadis Pharma ; The Medical College of Wisconsin; Merck & Co, Inc. ; Millennium: The Takeda Oncology Co. ; Milliman USA, Inc. ; Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Optum Healthcare Solutions, Inc. ; Osiris Therapeutics, Inc. ; Otsuka America Pharmaceutical, Inc. ; RemedyMD ; Sanofi ; Seattle Genetics ; Sigma-Tau Pharmaceuticals ; Soligenix, Inc. ; StemCyte, A Global Cord Blood Therapeutics Co. ; Stemsoft Software, Inc. ; Swedish Orphan Biovitrum ; Tarix Pharmaceuticals ; Teva Neuroscience, Inc. ; Therakos ; and WellPoint The views expressed in this article do not reflect the official policy or position of the NIH, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government. Publisher Copyright: {\textcopyright} 2015 American Society for Blood and Marrow Transplantation.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.bbmt.2014.10.021",

language = "English (US)",

volume = "21",

pages = "266--274",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation

T2 - A Report from the Center for International Blood and Marrow Transplant Research

AU - Arai, Sally

AU - Arora, Mukta

AU - Wang, Tao

AU - Spellman, Stephen R.

AU - He, Wensheng

AU - Couriel, Daniel R.

AU - Urbano-Ispizua, Alvaro

AU - Cutler, Corey S.

AU - Bacigalupo, Andrea A.

AU - Battiwalla, Minoo

AU - Flowers, Mary E.

AU - Juckett, Mark B.

AU - Lee, Stephanie J.

AU - Loren, Alison W.

AU - Klumpp, Thomas R.

AU - Prockup, Susan E.

AU - Ringdén, Olle T H

AU - Savani, Bipin N.

AU - Socié, Gérard

AU - Schultz, Kirk R.

AU - Spitzer, Thomas

AU - Teshima, Takanori

AU - Bredeson, Christopher N.

AU - Jacobsohn, David A.

AU - Hayashi, Robert J.

AU - Drobyski, William R.

AU - Frangoul, Haydar A.

AU - Akpek, Görgün

AU - Ho, Vincent T.

AU - Lewis, Victor A.

AU - Gale, Robert Peter

AU - Koreth, John

AU - Chao, Nelson J.

AU - Aljurf, Mahmoud D.

AU - Cooper, Brenda W.

AU - Laughlin, Mary J.

AU - Hsu, Jack W.

AU - Hematti, Peiman

AU - Verdonck, Leo F.

AU - Solh, Melhelm M.

AU - Norkin, Maxim

AU - Reddy, Vijay

AU - Martino, Rodrigo

AU - Gadalla, Shahinaz

AU - Goldberg, Jenna D.

AU - McCarthy, Philip L.

AU - Pérez-Simón, José A.

AU - Khera, Nandita

AU - Lewis, Ian D.

AU - Atsuta, Yoshiko

AU - Olsson, Richard F.

AU - Saber, Wael

AU - Waller, Edmund K.

AU - Blaise, Didier

AU - Pidala, Joseph A.

AU - Martin, Paul J.

AU - Satwani, Prakash

AU - Bornhäuser, Martin

AU - Inamoto, Yoshihiro

AU - Weisdorf, Daniel J.

AU - Horowitz, Mary M.

AU - Pavletic, Steven Z.

N1 - Funding Information: Financial disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI) (U24-CA76518), and the National Institute of Allergy and Infectious Diseases (NIAID) (U24-CA76518); Grant/Cooperative Agreement 5U01HL069294 from the NHLBI and NCI ; contract HHSH234200637015C with Health Resources and Services Administration; 2 grants ( N00014-06-1-0704 and N00014-08-1-0058 ) from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast; Anonymous donation to the Medical College of Wisconsin; Ariad ; Be The Match Foundation ; Blue Cross and Blue Shield Association ; Buchanan Family Foundation ; CaridianBCT ; Celgene Corporation ; CellGenix , GmbH ; Fresenius-Biotech North America, Inc. ; Gamida Cell Teva Joint Venture Ltd. ; Genentech, Inc. ; Genzyme Corporation ; GlaxoSmithKline ; HistoGenetics, Inc. ; Kiadis Pharma ; The Medical College of Wisconsin; Merck & Co, Inc. ; Millennium: The Takeda Oncology Co. ; Milliman USA, Inc. ; Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Optum Healthcare Solutions, Inc. ; Osiris Therapeutics, Inc. ; Otsuka America Pharmaceutical, Inc. ; RemedyMD ; Sanofi ; Seattle Genetics ; Sigma-Tau Pharmaceuticals ; Soligenix, Inc. ; StemCyte, A Global Cord Blood Therapeutics Co. ; Stemsoft Software, Inc. ; Swedish Orphan Biovitrum ; Tarix Pharmaceuticals ; Teva Neuroscience, Inc. ; Therakos ; and WellPoint The views expressed in this article do not reflect the official policy or position of the NIH, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government. Publisher Copyright: © 2015 American Society for Blood and Marrow Transplantation.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio=1.19, P<.0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.

AB - Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio=1.19, P<.0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.

KW - Allogeneic transplant

KW - CGVHD

KW - Incidence

KW - Nonrelapse mortality

UR - http://www.scopus.com/inward/record.url?scp=84920903701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920903701&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.10.021

DO - 10.1016/j.bbmt.2014.10.021

M3 - Article

C2 - 25445023

AN - SCOPUS:84920903701

SN - 1083-8791

VL - 21

SP - 266

EP - 274

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 2

ER -

Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this